ArticleVascular health and risk management2026
Association Between Apelin Gene -1860T>C (rs56204867) Polymorphism and Coronary Artery Disease in a Syrian Cohort.
Article in Vascular health and risk management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Apelin is a secreted peptide hormone involved in vasodilation, fluid homeostasis, and angiogenesis, and is therefore considered an important regulator of cardiovascular physiology. The APLN T-1860C (rs56204867) polymorphism is a genetic variation in the promoter region of the apelin gene (APLN) that is associated with increased susceptibility to cardiovascular risk factors. This study aimed to elucidate the relationship between the apelin gene -1860T>C single-nucleotide polymorphism, plasma apelin levels, and the risk of coronary artery disease (CAD) in a Syrian population. Patients and Methods: A case-control study was conducted, comprising 108 CAD patients and 114 healthy controls. Plasma apelin levels were quantified using an enzyme-linked immunosorbent assay (ELISA). The apelin -1860T>C gene polymorphism was analyzed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Results: Our findings reveal that mean plasma apelin levels were significantly lower in CAD patients (2737.81 ± 1205.01 pg/mL) compared to controls (4258.73 ± 2119.12 pg/mL; p < 0.001). Notably, these levels did not correlate with any of the other anthropometric parameters studied. In females, the frequencies of the TC genotype (30.5% vs 10.5%, p = 0.041, odds ratio [OR] = 3.75) and the mutant C allele (15.2% vs 5.2%, p = 0.043, OR = 3.256) were significantly higher in CAD patients than in controls. Whereas no significant differences were observed in male subjects. Although the plasma apelin level was lower in patients and controls with the TC genotype, this difference was not statistically significant (p > 0.05). Conclusion: Our findings indicate that the APLN -1860T>C polymorphism is associated with a higher risk of CAD in the Syrian population, particularly among females, suggesting a sex-specific genetic predisposition. Furthermore, reduced plasma apelin levels in patients suggest that apelin may play an independent role in the development of CAD, warranting further exploration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.